Unlock instant, AI-driven research and patent intelligence for your innovation.

Radiolabelling via fluorination of aziridines

An aziridine ring and labeling technology, applied in the field of positron emission tomography, can solve problems such as inapplicability

Inactive Publication Date: 2009-11-11
BAYER SCHERING PHARMA OY
View PDF10 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0033] Furthermore, the high temperatures used are not suitable for sensitive bioactive molecules such as peptides used here as targeting agents.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Radiolabelling via fluorination of aziridines
  • Radiolabelling via fluorination of aziridines
  • Radiolabelling via fluorination of aziridines

Examples

Experimental program
Comparison scheme
Effect test

no. 1 example

[0406] Azeotropic drying in the presence of Kryptofix 222 (5 mg in 1.5 ml MeCN) and cesium carbonate (2.3 mg in 0.5 ml water) by heating at 100-120 °C for 20-30 min in a nitrogen stream 18 F-Fluoride (up to 40GBq). During this time, 3 x 1 ml MeCN was added and evaporated. After drying, the precursor solution (2 mg) in 150 μl DMSO was added. Seal the reactor, then heat in the range of 50-70°C for 5-15min to complete the labeling. The reaction was cooled to room temperature then diluted with water (2.7ml). The crude reaction mixture was analyzed by analytical HPLC. The expected by preparative radiation HPLC 18 F labeled peptide.

[0407] Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest potential. The following preferred specific embodiments should therefore be considered as illustrative only and not limiting in any way to the remainder of the disclosure.

[0408] All ...

Embodiment 1

[0439] Preparation of compounds of general chemical formula I and corresponding model compounds

[0440] Prepared according to Scheme 1 when n=0.

[0441] Preparation of methyl 1-trityl-ziridine-2-carboxylate 2a

[0442]

[0443] 3g (29.6mmol) of aziridine 1a was dissolved in 50ml of dichloromethane, cooled to 0°C, and then 6.17ml (44.51mmol) of triethylamine and 9.93g (35.61mmol) of trityl chloride were added. The mixture was stirred at room temperature for 2 h, then concentrated. The residue was purified by chromatography on silica gel to afford 9.96 g (98%) of 2a.

[0444] 1 H-NMR (CDCl 3 ): δ=7.41 (m, 6H), 7.30-7.17 (m, 9H), 3.77 (s, 3H), 2.26 (dd, 1H), 1.89 (dd, 1H), 1.42 (dd, 1H) ppm.

[0445] Preparation of 1-trityl-aziridine-2-carboxylic acid 3a

[0446]

[0447] 7.45 g (21.69 mmol) of 2a were dissolved in 55 ml THF, cooled to °C and then treated with 34.7 ml (34.71 mmol) 1N sodium hydroxide solution. The reaction mixture was stirred overnight at room temp...

Embodiment 2

[0533] Preparation of compounds of general chemical formula II and corresponding model compounds

[0534] When n=1, it is prepared according to route 2.

[0535] Preparation of (2-chlorosulfonyl-3,5-dimethoxy-phenyl)-acetic acid methyl ester 14a

[0536]

[0537] At -10°C, 0.4ml (6mmol) of chlorosulfonic acid was dissolved in 4ml of dichloromethane, followed by the slow addition of 600mg (2.85mmol) of (3,5-dimethoxy-2-methane) dissolved in 2ml of dichloromethane yl-phenyl)-acetic acid methyl ester 13a. The reaction mixture was stirred at room temperature for 1 h, diluted with 50 mL of ethyl acetate and washed with 10 mL of saturated sodium bicarbonate solution. The phases were separated and the aqueous phase was extracted with ethyl acetate. The combined organic phases were washed with brine, dried over Na2SO4, filtered and concentrated to afford 451 mg (51%) of crude 14a, which was used in the next step without further purification.

[0538] 1 H-NMR (CDCl 3 ): δ = 6....

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to novel compounds suitable for or already radiolabeled with F, methods of making such compounds and use of such compounds for diagnostic imaging.

Description

field of invention [0001] The present invention relates to suitable or already used suitable fluorine isotopes (preferably 18 F) Labeled novel compounds, methods of preparing such compounds, compositions comprising such compounds, kits comprising such compounds or compositions and the use of such compounds, compositions or kits for diagnostic imaging, preferably For Positron Emission Tomography (PET). Background technique [0002] In the fields of oncology, neurology and cardiology, molecular imaging has the potential to detect disease progression or treatment efficacy earlier than most traditional methods. Among several promising molecular imaging techniques that have been developed such as optical imaging and MRI, positron emission tomography (PET) has attracted particular attention in drug development due to its high sensitivity and ability to provide quantitative and dynamic data. [0003] In the past few years, the use of PET for in vivo scanning has increased. PET i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07C311/19C07D203/08C07D487/04C07D203/24C07D487/22C07D207/14C07D491/04C07D403/12C07D405/04C07D405/14C07K7/02
CPCC07K1/13C07B39/00C07B59/001C07D203/18C07B59/002C07B2200/05C07D487/04C07D203/08A61K51/088C07C311/19
Inventor A·斯里尼瓦桑T·布伦比T·施特尔菲尔德K·格雷厄姆U·勒恩J·贝科穆林静
Owner BAYER SCHERING PHARMA OY